Closetinvestor, thank you for addressing my lazy post. It certainly appears that Synairgen’s inhaled interferon could be a very valuable therapeutic. My brief reading leads me to believe that inhaled Interferon-β could be very valuable in Covid.

The world needs all the help it can get. A therapy in mild/moderate patients, on top of a decent vaccine and leronlimab for severe and critical patients could restore normalcy to this world. It is abundantly clear that there is simply insufficient availability of leronlimab in the short term, regardless of who may partner with Cytodyn.

The previous (AstraZeneca) studies with exacerbation of asthma in cold symptoms were inconclusive with too few adverse events in placebo arm. Certainly not the case in the current trial with Covid.

It would be nice to have a landscape without significant competition. However, three deaths in Synairgen’s placebo arm indicates that the adverse events in Leronlimab trials may have similar disease progression / adverse events, boosting clinical significance of trial results.

Let’s hope that both drugs are available for all in need.